Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HSK47388 in Healthy Volunteers
NCT06926218Phase 1Not yet recruiting
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- May 2025
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in plaque psoriasis comparing HSK47388 with Placebo (2 arms). Primary endpoint: Number of participants with treatment-related adverse events as assessed by CTCAE at 7 days. Planned start May 2025; status: not yet recruiting.
02
Drugs
HSK47388
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06926218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926218.